3378.HK
HANXBIO-B
HK$17.51
-3.58%
2026-02-27
About HANXBIO-B
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Key Fundamentals
EPS (TTM)
HK$-1.28
ROE
-27.3%
Profit Margin
0.0%
Price/Book
0.48
Market Cap
HK$3.87B
Avg Volume (10D)
70K
Recent Breakout Signals
No recent breakout signals detected for 3378.HK.
Recent Price Range (60 Days)
60D High
HK$29.48
60D Low
HK$13.48
Avg Volume
407K
Latest Close
HK$17.51
Get breakout alerts for 3378.HK
Sign up for Breakout Scanner to receive daily notifications when 3378.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
HANXBIO-B (3378.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 3378.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 3378.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.